Adefovir: Difference between revisions
No edit summary |
|||
| Line 24: | Line 24: | ||
'''| [[Adefovir how supplied|How Supplied]]''' | '''| [[Adefovir how supplied|How Supplied]]''' | ||
'''| [[Adefovir labels and packages|Labels and Packages]]''' | '''| [[Adefovir labels and packages|Labels and Packages]]''' | ||
===Pill Images=== | |||
{{TempDrugImages}} | |||
{{PillImage|fileName=Hepsera_NDC_619580501.jpg|drugName=Hepsera|NDC=619580501|drugAuthor=Gilead Sciences, Inc.|ingredients=adefovir dipivoxil[adefovir]|pillImprint=Gilead;10|dosageValue=10|dosageUnit=mg|pillColor=White|pillShape=Round|pillSize=7|pillScore=1}} | |||
==Mechanism of Action== | ==Mechanism of Action== | ||
Adefovir is an acyclic nucleotide analog of adenosine monophosphate which is phosphorylated to the active metabolite adefovir diphosphate by cellular kinases. Adefovir diphosphate inhibits HBV DNA polymerase (reverse transcriptase) by competing with the natural substrate deoxyadenosine triphosphate and by causing DNA chain termination after its incorporation into viral DNA. The inhibition constant (Ki) for adefovir diphosphate for HBV DNA polymerase was 0.1 µM. Adefovir diphosphate is a weak inhibitor of human DNA polymerases α and γ with Ki values of 1.18 µM and 0.97 µM, respectively. | Adefovir is an acyclic nucleotide analog of adenosine monophosphate which is phosphorylated to the active metabolite adefovir diphosphate by cellular kinases. Adefovir diphosphate inhibits HBV DNA polymerase (reverse transcriptase) by competing with the natural substrate deoxyadenosine triphosphate and by causing DNA chain termination after its incorporation into viral DNA. The inhibition constant (Ki) for adefovir diphosphate for HBV DNA polymerase was 0.1 µM. Adefovir diphosphate is a weak inhibitor of human DNA polymerases α and γ with Ki values of 1.18 µM and 0.97 µM, respectively. | ||
==References== | ==References== | ||
Revision as of 17:51, 2 July 2014
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Adefovir dipivoxil, previously called bis-POM PMEA, with trade names Preveon® and Hepsera®, is an orally-administered nucleotide analog reverse transcriptase inhibitor (ntRTI) used for treatment of hepatitis B. It is a failed treatment for HIV.
Category
Antiviral
US Brand Names
HEPSERA®
FDA Package Insert
Description | Clinical Pharmacology | Microbiology | Indications and Usage | Contraindications | Warnings and Precautions | Adverse Reactions | Overdosage | Clinical Studies | Dosage and Administration | How Supplied | Labels and Packages
Pill Images
{{#ask: Page Name::Adefovir |?Pill Name |?Drug Name |?Pill Ingred |?Pill Imprint |?Pill Dosage |?Pill Color |?Pill Shape |?Pill Size (mm) |?Pill Scoring |?NDC |?Drug Author |format=template |template=DrugPageImages |mainlabel=- |sort=Pill Name }} {{#subobject:
|Page Name=Adefovir |Pill Name=Hepsera_NDC_619580501.jpg |Drug Name=Hepsera |Pill Ingred=adefovir dipivoxil[adefovir]|+sep=; |Pill Imprint=Gilead;10 |Pill Dosage=10 mg |Pill Color=White|+sep=; |Pill Shape=Round |Pill Size (mm)=7 |Pill Scoring=1 |Pill Image= |Drug Author=Gilead Sciences, Inc. |NDC=619580501
}}
Mechanism of Action
Adefovir is an acyclic nucleotide analog of adenosine monophosphate which is phosphorylated to the active metabolite adefovir diphosphate by cellular kinases. Adefovir diphosphate inhibits HBV DNA polymerase (reverse transcriptase) by competing with the natural substrate deoxyadenosine triphosphate and by causing DNA chain termination after its incorporation into viral DNA. The inhibition constant (Ki) for adefovir diphosphate for HBV DNA polymerase was 0.1 µM. Adefovir diphosphate is a weak inhibitor of human DNA polymerases α and γ with Ki values of 1.18 µM and 0.97 µM, respectively.